Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH3A1 | P30838 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22725406 | 0.82 | KAT2B (0.58) | ALDH1A1LMNAPOLBMAPTSMN1; SMN2 | |
| SCHEMBL2019323 | 0.81 | LMNA (0.72) | PKMALDH1A1KMT2AMEN1ALDH3A1 | |
| SCHEMBL6414763 | 0.81 | KDM4E (0.50) | PKMKMT2AMEN1MAPTTDP1 | |
| SCHEMBL22725430 | 0.81 | MAPT (0.61) | PKMALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL10485197 | 0.81 | PKM (0.65) | PKMALDH1A1KMT2AMEN1ALDH3A1 | |
| SCHEMBL6261849 | 0.81 | MAPT (0.46) | PKMALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL6274888 | 0.78 | STAT3 (0.63) | PKMALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL31327395 | 0.77 | ALDH1A1 (0.56) | PKMALDH1A1KMT2AMEN1ALDH3A1 | |
| SCHEMBL6278066 | 0.77 | MAPT (0.54) | ALDH1A1KMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL10485359 | 0.76 | KMT2A (0.57) | PKMALDH1A1KMT2AMEN1ALDH3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050209284-A1 | Tec kinase inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | US | disclosed |
| WO-2005079791-A1 | THIOPHENE -2- CARBOXYLIC ACID - (1H - BENZIMIDAZOL - 2 YL) - AMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE TEC KINASE ITK (INTERLEUKIN -2- INDUCIBLE T CELL KINASE) FOR THE TREATMENT OF INFLAMMATION, IMMUNOLOGICAL AND ALLERGIC DISORDERS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209284-A1 | Tec kinase inhibitors | TEC, ITK, TXK | PKM 997/4885ALDH1A1 3145/4885KMT2A 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.